Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Derivative exercise or conversion — not an open-market buy.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Nov 2, 2026
Reporting period
Not applicable
Filed with the SEC
Nov 3, 2026
DirectorIndirect holdingOption exercise
Context
Classification
option exercise
Code C — exercise or conversion of a derivative security
Planned / mechanical clue
None found in footnotes
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001231919-26-001533
Filed / recorded
Nov 3, 2026, 11:09 PM UTC
Added to OQRO
Nov 3, 2026, 11:15 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
Bambusa Therapeutics, Inc.
Issuer CIK
2044950
Ticker
BBTX
Reporting person
RA CAPITAL MANAGEMENT, L.P.
Relationship
Director, 10% owner
Security
Series A-1 Preferred Stock
Table
Derivative (Table II)
Transaction date
Nov 2, 2026
Transaction code
C
Shares / units
2,844,910
Price per share
$0.00
Acquired / disposed
Disposed (D)
Shares owned after
0
Ownership form
Indirect — See footnotes
Amendment
No
Footnotes from the filing
All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") prior to the closing of the Issuer's initial public offering of its Common Stock.
RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
A Schedule 13D means the holder owns more than 5% and keeps the option to push for changes: board seats, a sale, buybacks. It must be filed within 5 business days.
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
A Bambusa Therapeutics director paid $2.7M out of pocket for Bambusa Therapeutics shares. 2 other people at Bambusa Therapeutics bought some too, in the same month.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.